John Libbey Eurotext

Annales de Biologie Clinique

Peptides natriurétiques : dégradation, formes circulantes, dosages et nouvelles approches thérapeutiques Volume 75, numéro 3, Mai-Juin 2017

  • [1] Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016 ; 37 : 2129-200.
  • [2] McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Bohm M., Dickstein K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803-869.
  • [3] Maisel A., Mueller C., Adams K. Jr., Anker S.D., Aspromonte N., Cleland J.G. State of the art : using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10:824-839.
  • [4] Nieminen M.S., Bohm M., Cowie M.R., Drexler H., Filippatos G.S., Jondeau G. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure : the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384-416.
  • [5] Januzzi J.L. Jr., Camargo C.A., Anwaruddin S., Baggish A.L., Chen A.A., Krauser D.G. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948-954.
  • [6] Januzzi J.L., van Kimmenade R., Lainchbury J., Bayes-Genis A., Ordonez-Llanos J., Santalo-Bel M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure : an international pooled analysis of 1256 patients : the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330-337.
  • [7] Martinez-Rumayor A., Richards A.M., Burnett J.C., Januzzi J.L. Jr. Biology of the natriuretic peptides. Am J Cardiol. 2008;101:3-8.
  • [8] Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E. Jr., Drazner M.H. 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-239.
  • [9] Maisel A., Mueller C., Nowak R., Peacock W.F., Landsberg J.W., Ponikowski P. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea : results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55:2062-2076.
  • [10] de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Reprinted from Life Sci 1981 ; 28 : 89-94. J Am Soc Nephrol 2001 ; 12 : 403-9 ; discussion : 03-8, 08-9.
  • [11] Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004;6:257-260.
  • [12] Sudoh T., Minamino N., Kangawa K., Matsuo H. Brain natriuretic peptide-32 : N-terminal six amino acid extended form of brain natriuretic peptide identified in porcine brain. Biochem Biophys Res Com. 1988;155:726-732.
  • [13] Shimizu H., Masuta K., Aono K., Asada H., Sasakura K., Tamaki M. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta. 2002;316:129-135.
  • [14] Gorenjak M. Natriuretic peptides in assessment of ventricular dysfunction. EJIFCC. 2003;13:1-3.
  • [15] Yandle T.G., Richards A.M. B-type natriuretic peptide circulating forms : analytical and bioactivity issues. Clin Chim Acta. 2015;448:195-205.
  • [16] Jourdain P., Lefevre G., Oddoze C., Sapin V., Dievart F., Jondeau G. NT-proBNP in practice : from chemistry to medicine. Ann Biol Clin. 2009;67:255-271.
  • [17] Potter L.R. Natriuretic peptide metabolism, clearance and degradation. FEBS J. 2011;278:1808-1817.
  • [18] Clerico A., Iervasi G. Alterations in metabolic clearance of atrial natriuretic peptides in heart failure : how do they relate to the resistance to atrial natriuretic peptides ? J Cardiac Fail. 1995;1:323-328.
  • [19] Sherwood L. The urinary system. In : Human physiology. From cells to systems. 8e édition. Boston (USA) : Cengage Learning US, 2011 : 504-49.
  • [20] Cataliotti A., Chen H.H., Redfield M.M., Burnett J.C. Jr. Natriuretic peptides as regulators of myocardial structure and function : pathophysiologic and therapeutic implications. Heart Fail Clin. 2006;2:269-276.
  • [21] Calvieri C., Rubattu S., Volpe M. Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides. J Mol Med. 2012;90:5-13.
  • [22] Yandle T.G., Richards A.M., Gilbert A., Fisher S., Holmes S., Espiner E.A. Assay of brain natriuretic peptide (BNP) in human plasma : evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab. 1993;76:832-838.
  • [23] Hawkridge A.M., Heublein D.M., Bergen H.R. 3rd, Cataliotti A., Burnett J.C. Jr., Muddiman D.C. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA. 2005;102:17442-17447.
  • [24] Miller W.L., Phelps M.A., Wood C.M., Schellenberger U., Van Le A., Perichon R. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail. 2011;4:355-360.
  • [25] Niederkofler E.E., Kiernan U.A., O’Rear J., Menon S., Saghir S., Protter A.A. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail. 2008;1:258-264.
  • [26] Brandt I., Lambeir A.M., Ketelslegers J.M., Vanderheyden M., Scharpe S., De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem. 2006;52:82-87.
  • [27] Liang F., O’Rear J., Schellenberger U., Tai L., Lasecki M., Schreiner G.F. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol. 2007;49:1071-1078.
  • [28] Goetze J.P. Biochemistry of pro-B-type natriuretic peptide-derived peptides : the endocrine heart revisited. Clin Chem. 2004;50:1503-1510.
  • [29] Goetze J.P., Kastrup J., Rehfeld J.F. The paradox of increased natriuretic hormones in congestive heart failure patients : does the endocrine heart also fail in heart failure ? Eur Heart J. 2003;24:1471-1472.
  • [30] Januzzi J.L. Jr. B-type natriuretic peptide testing in the era of neprilysin inhibition : are the winds of change blowing ? Clin Chem. 2016;62:663-665.
  • [31] Luckenbill K.N., Christenson R.H., Jaffe A.S., Mair J., Ordonez-Llanos J., Pagani F. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays : preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem. 2008;54:619-621.
  • [32] Fujimoto H., Suzuki T., Aizawa K., Sawaki D., Ishida J., Ando J. Processed B-type natriuretic peptide is a biomarker of postinterventional restenosis in ischemic heart disease. Clin Chem. 2013;59:1330-1337.
  • [33] Foo J.Y., Wan Y., Schulz B.L., Kostner K., Atherton J., Cooper-White J. Circulating fragments of N-terminal pro-B-type natriuretic peptides in plasma of heart failure patients. Clin Chem. 2013;59:1523-1531.
  • [34] Schellenberger U., O’Rear J., Guzzetta A., Jue R.A., Protter A.A., Pollitt N.S. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys. 2006;451:160-166.
  • [35] Hughes D., Talwar S., Squire I.B., Davies J.E., Ng L.L. An immunoluminometric assay for N-terminal pro-brain natriuretic peptide : development of a test for left ventricular dysfunction. Clin Sci. 1999;96:373-380.
  • [36] Nishikimi T., Ikeda M., Takeda Y., Ishimitsu T., Shibasaki I., Fukuda H. The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart. 2012;98:152-161.
  • [37] Semenov A.G., Postnikov A.B., Tamm N.N., Seferian K.R., Karpova N.S., Bloshchitsyna M.N. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin Chem. 2009;55:489-498.
  • [38] Rosjo H., Dahl M.B., Jorgensen M., Roysland R., Brynildsen J., Cataliotti A. Influence of glycosylation on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea : data from the Akershus Cardiac Examination 2 Study. Clin Chem. 2015;61:1087-1097.
  • [39] McMurray J.J. Neprilysin inhibition to treat heart failure : a tale of science, serendipity, and second chances. Eur J Heart Fail. 2015;17:242-247.
  • [40] O’Connor C.M., Starling R.C., Hernandez A.F., Armstrong P.W., Dickstein K., Hasselblad V. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32-43.
  • [41] Hamaguchi S., Kinugawa S., Tsuchihashi-Makaya M., Goto D., Yamada S., Yokoshiki H. Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure-A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). J Cardiol. 2013;62:95-101.
  • [42] Ichiki T., Huntley B.K., Sangaralingham S.J., Burnett J.C. Jr. Pro-atrial natriuretic peptide : a novel guanylyl cyclase-A receptor activator that goes beyond atrial and B-type natriuretic peptides. JACC Heart Fail. 2015;3:715-723.
  • [43] McKie P.M., Ichiki T., Burnett J.C. Jr. M-atrial natriuretic peptide : a novel antihypertensive protein therapy. Curr Hypertens Rep. 2012;14:62-69.
  • [44] McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
  • [45] Solomon S.D., Zile M., Pieske B., Voors A., Shah A., Kraigher-Krainer E. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction : a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387-1395.
  • [46] Packer M., Califf R.M., Konstam M.A., Krum H., McMurray J.J., Rouleau J.L. Comparison of omapatrilat and enalapril in patients with chronic heart failure : the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation. 2002;106:920-926.
  • [47] Semenov A.G., Katrukha A.G. Different susceptibility of B-type natriuretic peptide (BNP) and BNP orecursor (proBNP) to cleavage by neprilysin : the N-terminal part does matter. Clin Chem. 2016;62:617-622.